LIVE

Serial Number

79238591

Owner

NMD Pharma A/S

Attorney

Joel D. Leviton

Filing Date

May 18, 2018

Add to watchlist:

No watchlists yet

+ Create New Watchlist

View on USPTO

NMD NEUROMUSCULAR DISORDERS Trademark

Serial Number: 79238591 • Registration: 5809159

NMD NEUROMUSCULAR DISORDERS is a trademark filed by NMD Pharma A/S on May 18, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Trademark Classes

Class 5 - Pharmaceuticals

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Class 42 - Computer & Scientific

Scientific and technological services; industrial analysis and research services

Owner Contact Info

NMD Pharma A/S (4 trademarks)

Palle Juul-Jensens Boulevard 82

Entity Type: 98

Legal Representation

Attorney of Record

Joel D. Leviton

1,949 trademarks filed View all →

Correspondence Address

Joel D. Leviton STINSON LLP

50 SOUTH 6TH STREET, STE 2600

MINNEAPOLIS, MN 55402

UNITED STATES

Trademark Details

Filing Date

May 18, 2018

Registration Date

July 23, 2019

Published for Opposition

May 7, 2019

Cancellation Date

February 6, 2026

Goods & Services

Chemical-pharmaceutical preparations for the treatment of rare and genetic diseases; chemical-pharmaceutical preparations for the treatment of neurodegenerative diseases; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders; chemical-pharmaceutical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by compromised skeletal muscle excitability; diagnostic preparations for medical purposes; reagents for medical purposes [ and for research ] ; preparations for analysis for medical [ and research ] purposes; pharmaceutical and medical preparations for the treatment of rare and genetic diseases; pharmaceutical and medical preparations for the treatment of neurodegenerative diseases; pharmaceutical and medical preparations for the treatment of neuromuscular disorders; pharmaceutical and medical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; pharmaceutical and medical preparations for acute hospital care, namely, chemical-pharmaceutical preparations for the reversal of neuromuscular blockade, chemical-pharmaceutical preparations for the treatment of intensive care unit acquired muscle weakness, chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by infections

Scientific and technological services and research, namely, research in the field of medicine and the development of pharmaceutical preparations; industrial analysis and research services in the field of development of pharmaceutical preparations, and in the field of identification of drug candidates; drug discovery services; basic research and clinical research, hereunder in the field of medicine and vaccine development; development of medical treatments related to rare and genetic diseases; development of medical treatments related to neurodegenerative diseases; development of medical treatments related to neuromuscular disorders; development of medical treatments that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; development of medical treatments for acute hospital care

Filing History

CANCELLED SECTION 71

Feb 6, 2026 C71T

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

Jul 23, 2024 REM3

CHANGE OF NAME/ADDRESS REC'D FROM IB

Sep 9, 2023 ADCH

INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE

Aug 29, 2020 INNA

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED

Jul 26, 2020 INPR

FINAL DECISION TRANSACTION PROCESSED BY IB

Dec 6, 2019 FINO

CORRECTION UNDER SECTION 7 - PROCESSED

Nov 21, 2019 COC.

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

Nov 21, 2019 APRE

FINAL DISPOSITION NOTICE SENT TO IB

Nov 14, 2019 FICS

LIMITATION FROM THE IB EXAMINED AND ENTERED

Nov 14, 2019 LIME

FINAL DISPOSITION PROCESSED

Nov 14, 2019 FIMP

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

Oct 23, 2019 FICR

LIMITATION OF GOODS RECEIVED FROM IB

Aug 23, 2019 LIMG

REGISTERED-PRINCIPAL REGISTER

Jul 23, 2019 R.PR

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

May 7, 2019 NPUB

PUBLISHED FOR OPPOSITION

May 7, 2019 PUBO

NOTIFICATION PROCESSED BY IB

May 3, 2019 GPNX

TEAS CHANGE OF CORRESPONDENCE RECEIVED

Apr 30, 2019 TCCA

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

Apr 17, 2019 OPNS

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

Apr 17, 2019 NONP

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

Apr 17, 2019 OP2R

APPROVED FOR PUB - PRINCIPAL REGISTER

Mar 18, 2019 CNSA

EXAMINER'S AMENDMENT ENTERED

Mar 18, 2019 XAEC

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

Mar 18, 2019 GNEN

EXAMINERS AMENDMENT E-MAILED

Mar 18, 2019 GNEA

EXAMINERS AMENDMENT -WRITTEN

Mar 18, 2019 CNEA

TEAS/EMAIL CORRESPONDENCE ENTERED

Mar 5, 2019 TEME

CORRESPONDENCE RECEIVED IN LAW OFFICE

Mar 4, 2019 CRFA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

Mar 4, 2019 TROA

REFUSAL PROCESSED BY IB

Oct 13, 2018 RFNT

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

Sep 21, 2018 RFCS

REFUSAL PROCESSED BY MPU

Sep 21, 2018 RFRR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

Sep 18, 2018 RFCR

NON-FINAL ACTION WRITTEN

Sep 17, 2018 CNRT

ASSIGNED TO EXAMINER

Sep 10, 2018 DOCK

APPLICATION FILING RECEIPT MAILED

Aug 24, 2018 MAFR

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Aug 20, 2018 NWOS

SN ASSIGNED FOR SECT 66A APPL FROM IB

Aug 16, 2018 REPR

Related Trademarks

More from this Owner

NMD NEUROMUSCULAR DISORDERS

NMD PHARMA NEUROMUSCULAR DISORDERS

More in Same Class

ZEN GUMMY

MEDISAL

SWEAT CREAM

CATS MOVE US. WE HELP MOVE THEM.

PRONASE

DOGS MOVE US. WE HELP MOVE THEM.